DURHAM, N.C. — bioMerieux, a medical diagnostics company with U.S. headquarters in Durham, has acquired Bacterial Barcodes, a provider of molecular biotechnology.
With the deal, bioMerieux secured Bacterial Barcodes’ DiversiLab technology, which can be used to infections acquired at hospitals. It also can be utilized to track problems in food supplies, such as E.coli, pharmaceuticals or an incident of bioterrorism.
DiversiLab is an automated system for strain typing and improved genotypic characterization of bacteria, yeast and molds, to help identify the sources of infections. It can produce results in as little as four hours compared to as long as four days for manual screening, according to bioMerieux.
“The addition of this innovative and timely solution to bioMÃ©rieux’s technology portfolio is perfectly aligned with the company’s strategic commitment to focus on infectious diseases, as well as on industrial applications,” said Eric Bouvier, chief executive officer of North American operations for bioMÃ©rieux. “It will advance bioMÃ©rieux’s rapid growth in the field of molecular biology.”
Terms of the deal were not disclosed.